BPC-157: The Complete Research Guide

What is BPC-157?

BPC-157 — short for Body Protection Compound-157 — is a synthetic pentadecapeptide, meaning a single chain of 15 amino acids. Its sequence is based on a stable partial fragment of a larger protein known as BPC (Body Protection Compound), which was originally identified in human gastric juice. Because it is produced synthetically, research-grade BPC-157 is a defined, reproducible molecule rather than a biological extract.

In the literature the 15-residue sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is frequently noted for being stable in aqueous solution, which is part of why it is such a common subject of preclinical study. Throughout this guide it is discussed strictly as a laboratory research compound — it is not a medicine and is intended for research use only.

Where BPC-157 comes from

BPC-157 is a fragment of a naturally occurring protein. The parent compound, Body Protection Compound, was isolated from human gastric juice, and researchers identified a short, stable 15-amino-acid region within it that retained interesting properties on its own. That fragment — synthesized independently — is what the research community refers to as BPC-157.

• Class — synthetic pentadecapeptide (15 amino acids).
• Origin — a partial sequence of the BPC protein found in gastric juice.
• Notable property — frequently characterized in the literature as stable in aqueous and acidic environments.
• Form supplied — a lyophilized (freeze-dried) powder for laboratory research use only.

How BPC-157 is studied: mechanisms of interest

BPC-157 draws research attention because of the pathways it appears to interact with. These mechanisms are how the compound is characterized in the published literature — they describe what is being studied, not confirmed outcomes:

• Angiogenesis (VEGF signaling) — studied for its association with new blood-vessel formation, including the vascular endothelial growth factor (VEGFR2) pathway.
• The nitric oxide (NO) system — research examines interactions with nitric oxide synthesis and related vascular signaling.
• Growth-factor pathways — investigated in connection with growth-factor expression and receptor signaling relevant to tissue models.
• Cell migration (FAK–paxillin pathway) — examined in cultured tendon and fibroblast models for its association with cell spreading and migration.

The recurring theme across these areas is angiogenesis and cell migration — processes central to how tissue models are studied. This is why BPC-157 is so often referenced in preclinical repair and recovery research rather than in any single, narrow context.

What the research explores

In preclinical laboratory research, BPC-157 is most often studied across a handful of interconnected areas:

• Tendon, ligament, muscle, and bone models — the tissue-repair research BPC-157 is best known for.
• Gastrointestinal / gut research — a natural focus given its origin as a gastric-juice-derived sequence.
• The gut–brain axis — signaling between the gastrointestinal tract and the central nervous system.
• Angiogenesis — new blood-vessel formation in tissue-repair and wound-healing research models.

BPC-157 vs. other repair & recovery research peptides

Researchers often place BPC-157 alongside other peptides studied in repair and recovery contexts. The clearest way to compare them is by their origin and the research focus each is most associated with:

Peptora carries research-grade BPC-157 alongside related repair-focused compounds, including the multi-peptide KLOW blend, and covers GHK-Cu in its own research guide. Each product ships with its own batch-specific certificate of analysis.

BPC-157, KLOW, and multi-peptide research blends

KLOW is Peptora's multi-peptide research blend, which combines BPC-157 with other repair- and recovery-oriented peptides in a single research vial. Researchers studying combined or comparative repair models sometimes reference blends like KLOW rather than sourcing each peptide separately. As with the standalone compound, KLOW is supplied strictly for laboratory research use only, with a batch-specific certificate of analysis so every component can be traced to its documentation.

Purity, testing & certificates of analysis

In research, the reliability of a result depends on the identity and purity of the material behind it. Every batch of BPC-157 from Peptora is HPLC-verified to 99%+ purity, confirmed by LC-MS identity testing, and screened across a full quality-control panel before release. Each order ships with a lot-specific certificate of analysis (COA) so the exact vial in hand can be matched to its documentation.

This documentation is standard rather than optional. To understand what each figure on a report means, see the guide on purity and certificates of analysis and the overview of testing standards.

Handling BPC-157 in the laboratory

BPC-157 is supplied as a lyophilized (freeze-dried) powder. Before research use it is reconstituted with bacteriostatic water, which is sold separately. Careful handling preserves peptide integrity and the validity of downstream work:

1. 1Allow the sealed vial to reach room temperature before opening.
2. 2Add bacteriostatic water slowly down the inside of the vial wall; swirl gently and never shake.
3. 3Let the powder dissolve completely before drawing any solution.
4. 4Store the reconstituted solution refrigerated and protected from light.

Full step-by-step protocols live in the reconstitution guide and the storage guide. Following them consistently is one of the simplest ways to keep research reproducible.

Scientific references

The literature below is provided for educational context, per PubMed, and describes preclinical and early-stage research on BPC-157 — which remains investigational and has not been evaluated in large, completed human clinical trials — as distinct from the laboratory research product supplied by Peptora.

1. 1Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System. Pharmaceuticals (Basel). 2025;18(6):928. doi:10.3390/ph18060928 (PMID: 40573323).
2. 2Seiwerth S, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Curr Pharm Des. 2018;24(18):1972-1989. doi:10.2174/1381612824666180712110447 (PMID: 29998800).
3. 3Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. doi:10.1007/s00109-016-1488-y (PMID: 27847966).
4. 4Sikiric P, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des. 2014;20(7):1126-1135. doi:10.2174/13816128113190990411 (PMID: 23755725).
5. 5Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. doi:10.3390/molecules191119066 (PMID: 25415472).
6. 6Cerovecki T, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161. doi:10.1002/jor.21107 (PMID: 20225319).